BioPharma Resources

Drug Trial Radar · NCT03488563

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine

Last checked: Nov 19, 2026Latest source record: Oct 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 313 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

313

Actual

Start

Mar 30, 2018

Primary completion

Jun 17, 2019

Study completion Jul 16, 2019

Sponsor

Lead sponsor
AOBiome LLCIndustry
Sponsor type
Industry
Collaborators
Veristat, Inc.
First posted
Apr 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic migraine.

Conditions

  • Migraine

Interventions

  • B244Biological

    B244 Suspension

  • VehicleBiological

    Vehicle Suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: Baseline to Day 112

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Baptist Health Center for Clinical Research

    Little Rock, Arkansas

  • Collaborative Neuroscience Network, LLC

    Long Beach, California

  • CI Trials

    Riverside, California

  • Neurological Research Institute

    Santa Monica, California

  • New England Institute for Neurology and Headache (NEINH)/Medical Practice

    Stamford, Connecticut

  • Clinical Neuroscience Solution, Inc

    Jacksonville, Florida

  • Precision Clinical Research

    Lauderdale Lakes, Florida

  • Clinical Neuroscience Solution, Inc

    Orlando, Florida

  • Palm Beach Research

    West Palm Beach, Florida

  • Neurostudies Clinical Research

    Decatur, Georgia

  • BTC of New Bedford

    New Bedford, Massachusetts

  • MedVadis Research

    Watertown, Massachusetts

  • Altea Research Institute

    Las Vegas, Nevada

  • Rochester Clinical Research INC

    Rochester, New York

  • PMG Research of Wilmington

    Wilmington, North Carolina

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Clinical Neuroscience Solution, Inc

    Memphis, Tennessee

  • FutureSearch Trials of Neurology and Sleep Lab, L.P.

    Austin, Texas

  • FutureSearch Trials of Dallas, L.P.

    Dallas, Texas

  • Texas Center for Drug Development

    Houston, Texas

  • Charlottesville Medical Research

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.